NCT05599919 is a Phase 3 clinical trial of Nitric Oxide in SARS-CoV-2 Infection, sponsored by Sanotize Research and Development corp..

Who is sponsoring NCT05599919?

NCT05599919 is sponsored by Sanotize Research and Development corp..

What drugs are being tested in NCT05599919?

Interventions in NCT05599919: Nitric Oxide.

What condition does NCT05599919 study?

NCT05599919 studies SARS-CoV-2 Infection.

Is NCT05599919 still recruiting?

NCT05599919 is currently completed. Last updated 31 October 2022.

Last reviewed 2022-10-31 · How we verify

NCT05599919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19

Completed Phase 3 Last updated 31 October 2022

What this trial tests

Phase 3 trial testing Nitric Oxide in SARS-CoV-2 Infection in 306 participants. Completed in 2 February 2022.

Timeline

1 November 2021

Primary endpoint
31 January 2022

2 February 2022

Quick facts

Lead sponsor	Sanotize Research and Development corp.
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	306
Start date	1 November 2021
Primary completion	31 January 2022
Estimated completion	2 February 2022
Sites	21 locations across India

Drugs / interventions tested

Nitric Oxide (NITRIC OXIDE) — full drug profile →

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

Sanotize Research and Development corp. — full company profile →

Who can join

Adults 18 to 65, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Primary: The primary objective of this study is to evaluate the efficacy of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization Secondary: The secondary objective is to evaluate the safety and tolerability of Nitric Oxide Nasal Spray combined with standard supportive care compared with standard supportive care alone in adult subjects with COVID-19 not requiring hospitalization.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nitric Oxide Signaling and Sensing in Age-Related Diseases.
Mazuryk O, Gurgul I, Oszajca M, Polaczek J, et al · · 2024 · cited 14× · PMID 39456466 · DOI 10.3390/antiox13101213

Verify or expand the search:

Other trials of Nitric Oxide

Trials testing the same drug.

NCT05801224 — Vascular ARDS Recruitment After Inhaled Nitric Oxide · NA · suspended
NCT06622291 — Perioperative Nitric Oxide Prevents Acute Kidney Injury in Acute Type A Aortic Dissection Patients · Phase 4 · completed
NCT04181359 — The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in Interstitial Lung Disease. · Phase 1, PHASE2 · withdrawn
NCT06120816 — Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis · Phase 1 · completed
NCT06660784 — Mechanism of Nitric Oxide on Ventilator-induced Diaphragm Dysfunction with Extracorporeal Membrane Lung Assistance · active not recruiting

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting

Other Sanotize Research and Development corp. trials

Trials by the same sponsor.

NCT06120816 — Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis · Phase 1 · completed
NCT06264141 — Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis · Phase 2 · active not recruiting
NCT05877313 — Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) · Phase 2 · completed
NCT05109611 — Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection · Phase 3 · terminated
NCT04755647 — Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05599919 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanotize Research and Development corp.
Last refreshed: 31 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05599919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing